JP2025502383A5 - - Google Patents

Info

Publication number
JP2025502383A5
JP2025502383A5 JP2024542372A JP2024542372A JP2025502383A5 JP 2025502383 A5 JP2025502383 A5 JP 2025502383A5 JP 2024542372 A JP2024542372 A JP 2024542372A JP 2024542372 A JP2024542372 A JP 2024542372A JP 2025502383 A5 JP2025502383 A5 JP 2025502383A5
Authority
JP
Japan
Prior art keywords
group
pharmaceutical formulation
hydrogen
alkyl
formulation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024542372A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025502383A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/010565 external-priority patent/WO2023141044A1/en
Publication of JP2025502383A publication Critical patent/JP2025502383A/ja
Publication of JP2025502383A5 publication Critical patent/JP2025502383A5/ja
Pending legal-status Critical Current

Links

JP2024542372A 2022-01-18 2023-01-11 代謝及び肝臓障害の処置のための医薬製剤及び方法 Pending JP2025502383A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263300538P 2022-01-18 2022-01-18
US63/300,538 2022-01-18
PCT/US2023/010565 WO2023141044A1 (en) 2022-01-18 2023-01-11 Pharmaceutical formulations and methods for the treatment of metabolic and liver disorders

Publications (2)

Publication Number Publication Date
JP2025502383A JP2025502383A (ja) 2025-01-24
JP2025502383A5 true JP2025502383A5 (cg-RX-API-DMAC10.html) 2026-01-20

Family

ID=87348890

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024542372A Pending JP2025502383A (ja) 2022-01-18 2023-01-11 代謝及び肝臓障害の処置のための医薬製剤及び方法

Country Status (11)

Country Link
US (1) US20250171499A1 (cg-RX-API-DMAC10.html)
EP (1) EP4466022A4 (cg-RX-API-DMAC10.html)
JP (1) JP2025502383A (cg-RX-API-DMAC10.html)
KR (1) KR20240136386A (cg-RX-API-DMAC10.html)
CN (1) CN118946368A (cg-RX-API-DMAC10.html)
AR (1) AR128285A1 (cg-RX-API-DMAC10.html)
AU (1) AU2023208627A1 (cg-RX-API-DMAC10.html)
CA (1) CA3248728A1 (cg-RX-API-DMAC10.html)
MX (1) MX2024008795A (cg-RX-API-DMAC10.html)
TW (1) TW202339789A (cg-RX-API-DMAC10.html)
WO (1) WO2023141044A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
CA3231953A1 (en) 2021-09-15 2023-03-23 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
WO2025209422A1 (en) * 2024-04-01 2025-10-09 Suzhou Spring-Sea Bio-Pharmaceuticals Co. Ltd. Incretin analogs as glp-1, gip and glucagon receptor triple agonists and uses thereof
WO2026092580A1 (en) 2024-10-30 2026-05-07 Ascletis Pharma (China) Co., Limited Glp-1r\gipr\gcgr modulator in combination with thr-beta modulator for treatment of metabolic diseases
WO2026092581A1 (en) 2024-10-30 2026-05-07 Ascletis Pharma (China) Co., Limited Thyroid hormone receptor beta modulator alone or in combination with a modulator of glp-1r, gipr or gcgr, for use in the treatment of obesity or overweight or for treating alopecia areata
WO2026092583A1 (en) 2024-10-30 2026-05-07 Ascletis Pharma (China) Co., Limited Thr-beta modulators, alone or in combination with glp-1r\gipr\gcgr modulators for the treatment of metabolic diseases and alopecia areata diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101243648B1 (ko) * 2003-11-20 2013-03-14 노보 노르디스크 에이/에스 제조 및 주사 장치용에 최적인 프로필렌 글리콜 함유펩티드 제제
TWI705820B (zh) * 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
KR20250044806A (ko) * 2018-07-23 2025-04-01 일라이 릴리 앤드 캄파니 요법을 위한 gip/glp1 공효능제 사용 방법
KR20240118914A (ko) * 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
JP2025523981A (ja) * 2022-07-20 2025-07-25 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための医薬製剤及び方法

Similar Documents

Publication Publication Date Title
US7371777B2 (en) Cyclic compound and PPAR agonist
US7687664B2 (en) Carboxylic acid derivative, a salt thereof or an ester of them, and medicament comprising it
EP1313471B1 (en) Benzylidene thiazolidinediones and their use as antimycotic agents
EP2307007B1 (en) Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation
US20160000810A1 (en) Method For Treating Eye Diseases
JP2017019854A (ja) 自己免疫性疾患の処置剤
KR20240136386A (ko) 대사 및 간 장애 치료를 위한 약학 제제 및 방법
WO2024020388A1 (en) Pharmaceutical formulations and methods for the treatment of metabolic and liver disorders
CN111315383A (zh) 共享表位-钙网蛋白相互作用的小分子抑制剂和使用方法
TW201618763A (zh) 用於預防及治療糖尿病之經取代之芳族化合物及醫藥組合物
CN101619061B (zh) 氰基吡啶基取代的噁唑烷酮类化合物
US20050070565A1 (en) Chelerythrine, analogs thereof and their use in the treatment of bipolar disorder and other cognitive disorders
US10065984B2 (en) Polymorphic forms of a steroid-like compound and methods for the preparation and use thereof
KR20110028199A (ko) 광학 활성 피페리딘 화합물의 개량된 제조방법
RU2024119883A (ru) Фармацевтические составы и способы лечения метаболических и печеночных расстройств
CA2425164C (en) (4-acylaminopiperidin-1-yl)acetamides as neurokinin antagonists
TW202425969A (zh) 吲唑吡啶酮化合物及其用途
WO2003070239A1 (en) Benzylidene thiazolidinediones and their use as antimycotic agents
WO2006097809B1 (en) Novel tyrosine derivatives
JP2006509022A5 (cg-RX-API-DMAC10.html)
RU2006142179A (ru) Соединения и композиции как ингибиторы катепсина s
US9737510B2 (en) Indazole compounds and a process for the preparation thereof
AU2013209344B2 (en) Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation
JP2023503470A5 (cg-RX-API-DMAC10.html)
CN103772376A (zh) 取代的苯并-1,3-杂唑类化合物、其制备方法及用途